BioCentury
ARTICLE | Financial News

Neurology play Denali planning $100M IPO

November 17, 2017 7:14 PM UTC

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting the offering.

Denali’s lead candidates include leucine-rich repeat kinase 2 (LRRK2) inhibitors DNL201 and DNL151, and receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitor DNL747...